Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The company’s RAS(ON) Inhibitors RMC-629 and RMC-6291 are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805, currently in IND-enabling development, RMC-8839, and additional compounds targeting...
Brand Name : RMC-5552
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2022
LOOKING FOR A SUPPLIER?